Results 81 to 90 of about 8,373 (204)

Clinical Outcome of Immunoglobulin Light Chain Amyloidosis Affecting the Kidney [PDF]

Blood, 2008
Abstract Introduction: The kidney is affected by immunoglobulin light chain amyloidosis (AL) in more than 50% of patients who present with the disease, but long-term predictors for and outcomes after renal replacement therapy have not been well described in this patient group Patients: 145 patients with AL who participated
Morie A, Gertz, Nelson, Leung, Martha Q, Lacy, Angela, Dispenzieri, Steven R, Zeldenrust, Suzanne R, Hayman, Francis K, Buadi, David, Dingli, Philip R, Greipp, Shaji K, Kumar, John A, Lust, S Vincent, Rajkumar, Stephen J, Russell, Thomas E, Witzig   +13 more
openaire   +2 more sources

Oxidative damage in immunoglobulin light chain and transthyretin cardiac amyloidosis – a closer look

Redox Experimental Medicine
Heart failure is a progressive disease, representing a growing cause of morbidity, hospitalization, and mortality. An increasingly common type of heart failure with preserved ejection fraction (HFpEF) is an immunoglobulin light chain and transthyretin ...
Elena Cavallone, Amir Hassan Mousavi, Carloalberto Biolé, Giulia Nangeroni, Alessandra Chinaglia, Matteo Bianco   +5 more
doaj   +1 more source

Nanoscopic Mapping of the Extracellular Space in Amyloid Plaque‐rich Cortex

Advanced Science, Volume 13, Issue 1, 5 January 2026.
The extracellular space and diffusion around amyloid plaques are examined using shadow imaging and single‐particle tracking. Increased diffusivity is found near plaques, extracellular matrix alterations, and plaque core penetrability that varies with amyloid phenotype.
Juan Estaún‐Panzano, Yulia Dembitskaya, Ivo Calaresu, Somen Nandi, Quentin Gresil, Evelyne Doudnikoff, Thierry Leste‐Lasserre, Thierry Amédée, Laurent Cognet, Laurent Groc, Urs Valentin Nägerl, Erwan Bezard   +11 more
wiley   +1 more source

The correlation of left atrial dysfunction and amyloid load in patients with immunoglobulin light-chain cardiac amyloidosis: a 3T cardiac magnetic resonance study [PDF]

, 2023
Jianyao Lu, Zhaoxia Yang, Dazong Tang, Yi Luo, Chunlin Xiang, Xiaoyue Zhou, Lu Huang, Liming Xia   +7 more
openalex   +1 more source

Navigating the evolving management of smoldering multiple myeloma

HemaSphere, Volume 10, Issue 1, January 2026.
Abstract Smoldering multiple myeloma (SMM) represents an intermediate clinical stage between monoclonal gammopathy of undetermined significance (MGUS) and symptomatic multiple myeloma (MM). SMM carries a highly variable risk of progression to MM, requiring individualized risk stratification to guide management.
M. Bakri Hammami, Rafael R. Canevarolo, Ariosto S. Silva, Melissa Alsina, Nagi Kumar, Rachid Baz, Kenneth H. Shain   +6 more
wiley   +1 more source

Pharmacological stabilization of the native state of full-length immunoglobulin light chains to treat light chain amyloidosis [PDF]

, 2023
N. Yan, Gareth J. Morgan, H. Michael Petrassi, Ian A. Wilson, Jeffery W. Kelly   +4 more
openalex   +1 more source

Bladder Amyloidosis With Pulmonary Lesions: A Case of Spontaneous Remission After Transurethral Resection

IJU Case Reports, Volume 9, Issue 1, January 2026.
ABSTRACT Introduction Bladder amyloidosis is a rare condition characterized by amyloid fibril deposition in the bladder, often mimicking bladder cancer. Diagnosis requires histological analysis of the examination, and treatment typically involves transurethral resection. Case Presentation An 80‐year‐old male presented with gross hematuria.
Suguru Ito, Takuma Suzuki, Ryo Sato, Kunihiko Maeda, Shinta Suenaga, Hidenori Kanno, Sadanobu Sato, Shigemitsu Horie, Sei Naito, Norihiko Tsuchiya   +9 more
wiley   +1 more source

Cutaneous light chain amyloidosis and erythema elevatum diutinum as the presenting features of IgA monoclonal gammopathy: a rare case report and comprehensive literature review

Annals of Hematology
Monoclonal gammopathy (MG) associated with dermatological disorders, which is classified as monoclonal gammopathy of clinical significance (MGCS), represents a well-established complication.
Bing Han, Junfeng Zhou, Hesong Liu, Shanshan Li, Hong Wang   +4 more
doaj   +1 more source

Central nervous system involvement in cardiac amyloidosis: Redefining the heart‐brain axis

European Journal of Clinical Investigation, Volume 56, Issue 1, January 2026.
Central nervous system involvement in cardiac amyloidosis. Amyloidosis is a systemic disease that can directly affect the central nervous system. Furthermore, the amyloid cardiomyopathy can indirectly affect the central nervous system by inducing systemic hypoperfusion and increasing the risk of acute ischaemic stroke.
Domenico Mario Giamundo, Giuliano Cassataro, Stefano Ministrini, Simon F. Stämpfli   +3 more
wiley   +1 more source

Púrpura: manifestação de amiloidose sistémica primária.

Acta Médica Portuguesa, 2009
Primary Systemic Amyloidosis (AL) is the most frequent form of systemic amyloidosis and its morbilility is associated with immunoglobulin light chains deposition in vital organs. The mucocutaneous manifestations occur in about 30-40% of the cases and are
Sara Lestre, Andreia Gonçalves, Alexandre João, Ana Ferreira, Margarida Apetato   +4 more
doaj   +1 more source